Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus

van Vollenhoven RF, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/ard-2022-222858.

Phase 3 study evaluating the efficacy and safety of ustekinumab in patients with active SLE, despite receiving standard-of-care, does not achieve primary and key secondary endpoints.

Read more…

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus

Dörner T, et al. Ann Rheum Dis. 2022. Epub ahead of print. doi:10.1136/annrheumdis-2022-222335.

Phase II study results suggest that baricitinib 4 mg downregulates key cytokines that are upregulated in patients with SLE.

Read more…

Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study

Rheumatology (Oxford). 2022;61(6):2413–2423 doi: 10.1093/rheumatology/keab685

Proof-of-concept study for the safety and efficacy of filgotinib (FIL) and lanraplenib (LANRA) in cutaneous lupus (CLE) fails to meet primary endpoint, but select subgroups displayed a numerically greater treatment response to FIL relative to placebo.

Read more…

Baricitinib decreases anti‑dsDNA in patients with systemic lupus erythematosus: results from a phase II double‑blind, randomized, placebo‑controlled trial

Arthritis Res Ther 2022;24(1):112 doi: 10.1186/s13075-022-02794-x

Evaluation of serological activity, including antibodies against double-stranded DNA (anti-dsDNA), suggests that baricitinib may influence B cell activity in systemic lupus erythematosus (SLE).

Read more…

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials

Ann Rheum Dis 2022;81:962–969 doi: 10.1136/annrheumdis-2021-221847

Bruce, et al. investigate the degree of concordance between BICLA and SRI-4 response across anifrolumab trials (TULIP-1, TULIP-2 and MUSE) in order to better understand drivers of discrepant systemic lupus erythematosus (SLE) trial results.

Read more…

Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

J Comp Eff Res. 2022;11(10):765–777 doi: 10.2217/cer-2022-0040

Population-adjusted comparative study provides insights for decision makers and clinicians about the comparative efficacy of anifrolumab and belimumab in patients with moderate-to-severe systemic lupus erythematosus (SLE) who are receiving standard therapy.

In the absence of head-to-head comparisons, Bruce, et al. assessed the comparative efficacy of the two biological therapies currently approved in the EU and USA for the treatment of moderate-to-severe SLE (anifrolumab 300 mg and belimumab 10 mg/kg).

After adjusting for important cross-trial differences, their results showed that anifrolumab was associated with significantly greater treatment benefits than belimumab.

Read more…

Biological impact of iberdomide in patients with active systemic lupus erythematosus

doi: 10.1136/annrheumdis-2022-222212

Phase 2b study evaluating the pharmacodynamics and pharmacokinetics of oral iberdomide in patients with active SLE demonstrates that iberdomide significantly improves lupus disease activity and reduces hallmarks of the immunopathogenesis of SLE.

Read more…

Impact of belimumab on organ damage in systemic lupus erythematosus

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24901

Review of clinical trial and real-world data on the effects of belimumab on organ damage in adult patients with SLE shows that belimumab reduces key drivers of organ damage, decreases organ damage progression and, in those with lupus nephritis (LN), decreases renal-related events.

Read more…

Race, Ethnicity, and Disparities in Risk of End-organ Lupus Manifestations Following SLE Diagnosis in a Multiethnic Cohort

Arthritis Care Res (Hoboken). 2022 Epub ahead of print doi: 10.1002/acr.24892

California Lupus Epidemiology Study (CLUES) finds heightened risks of developing renal, haematologic, and multiorgan disease following SLE diagnosis among Hispanic and Asian patients with SLE.

Read more…